omeprazole has been researched along with Colitis in 13 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "To clarify the effector sites of lansoprazole in the colonic mucosa during the formation of colitis, dextran sulfate sodium-induced colitis was induced by the oral administration of 3% aqueous solution for 3 and 7 days." | 7.73 | Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. ( Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T, 2005) |
| "To clarify the microvascular changes and the effector sites of lansoprazole during the formation of colitis, the dextran sulfate sodium (DSS)-induced colitis was induced by the oral administration for 3 and 7 days." | 7.73 | Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. ( Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K, 2006) |
| "A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole." | 7.71 | Collagenous colitis associated with lansoprazole. ( Mattia, A; Wilcox, GM, 2002) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 7.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "The authors report the case of a patient suffering from collagen colitis in whom the administration of omeprazole achieved the rapid and total abolition of the clinical signs and a significant reduction of the collagen band (measurements determined over 10 cryptic spaces using a graduated micrometric ocular microscope)." | 7.68 | [Value of omeprazole in the treatment of collagenous colitis]. ( Abinader, J; Becot, F; Carre, JL; Monnet, D; Piquemal, A; Roblin, X, 1991) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 5.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 5.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "To clarify the effector sites of lansoprazole in the colonic mucosa during the formation of colitis, dextran sulfate sodium-induced colitis was induced by the oral administration of 3% aqueous solution for 3 and 7 days." | 3.73 | Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. ( Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T, 2005) |
| "To clarify the microvascular changes and the effector sites of lansoprazole during the formation of colitis, the dextran sulfate sodium (DSS)-induced colitis was induced by the oral administration for 3 and 7 days." | 3.73 | Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites. ( Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K, 2006) |
| "A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole." | 3.71 | Collagenous colitis associated with lansoprazole. ( Mattia, A; Wilcox, GM, 2002) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 3.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "Omeprazole, 10 mg/kg, was given i." | 1.36 | Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. ( Chung, JW; Hahm, KB; Hong, KS; Kim, JH; Kim, YJ; Lee, JS, 2010) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 1.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 1.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YJ | 1 |
| Lee, JS | 1 |
| Hong, KS | 1 |
| Chung, JW | 1 |
| Kim, JH | 1 |
| Hahm, KB | 1 |
| Thomson, RD | 1 |
| Lestina, LS | 1 |
| Bensen, SP | 1 |
| Toor, A | 1 |
| Maheshwari, Y | 1 |
| Ratcliffe, NR | 1 |
| Mukherjee, S | 1 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Nakamura, M | 2 |
| Asada, M | 2 |
| Atsuda, K | 1 |
| Matsui, H | 2 |
| Watanabe, T | 1 |
| Higuchi, K | 1 |
| Arakawa, T | 1 |
| Hibi, N | 2 |
| Tsuchimoto, K | 2 |
| Inoue, J | 1 |
| Oda, M | 1 |
| Ottewell, PD | 1 |
| Duckworth, CA | 1 |
| Varro, A | 1 |
| Dimaline, R | 1 |
| Wang, TC | 1 |
| Watson, AJ | 1 |
| Dockray, GJ | 1 |
| Pritchard, DM | 1 |
| Pallarés Manrique, H | 1 |
| García Montes, MJ | 1 |
| Díaz Cano, S | 1 |
| Barranco Jiménez, M | 1 |
| Delgado Bellido, D | 1 |
| Herrerías Gutiérrez, JM | 1 |
| Ghilain, JM | 1 |
| Schapira, M | 1 |
| Maisin, JM | 1 |
| De Maeght, S | 1 |
| Piron, A | 1 |
| Gerard, R | 1 |
| Henrion, J | 1 |
| Wilcox, GM | 1 |
| Mattia, A | 1 |
| Macaigne, G | 1 |
| Boivin, JF | 1 |
| Simon, P | 1 |
| Chayette, C | 1 |
| Cheaib, S | 1 |
| Deplus, R | 1 |
| Narayani, RI | 1 |
| Burton, MP | 1 |
| Young, GS | 1 |
| Roblin, X | 1 |
| Becot, F | 1 |
| Abinader, J | 1 |
| Piquemal, A | 1 |
| Monnet, D | 1 |
| Carre, JL | 1 |
13 other studies available for omeprazole and Colitis
| Article | Year |
|---|---|
Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression.
Topics: Animals; Carcinoma; Cell Transformation, Neoplastic; Colitis; Colorectal Neoplasms; Disease Models, | 2010 |
Lansoprazole-associated microscopic colitis: a case series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Colitis; Co | 2002 |
Diarrhea associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastroin | 2003 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Infective Agents; Apoptosis; Autoradiography; | 2005 |
Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Binding Sites; Capillary Permeability; Colitis; Cy | 2006 |
Gastrin increases murine intestinal crypt regeneration following injury.
Topics: Animals; Benzodiazepinones; Cell Line; Cell Proliferation; Colitis; Dextran Sulfate; Enteritis; Enzy | 2006 |
[Collagenous colitis].
Topics: Adrenal Cortex Hormones; Adult; Colitis; Collagen Diseases; Diarrhea; Female; Humans; Middle Aged; O | 1993 |
[lymphocytic colitis associated with lansoprazole treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Diarrhea; Humans; Intestinal Mu | 2000 |
Collagenous colitis associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Collagen; Female; Humans; Lanso | 2002 |
[Lansoprazole-associated collagenous colitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Colitis; Collagen; Female; Gastroesophageal Reflux; | 2001 |
Resolution of collagenous colitis after treatment for Helicobacter pylori.
Topics: Aged; Biopsy, Needle; Clarithromycin; Colitis; Collagen; Diarrhea; Drug Therapy, Combination; Female | 2002 |
[Value of omeprazole in the treatment of collagenous colitis].
Topics: Administration, Oral; Colitis; Humans; Male; Middle Aged; Omeprazole | 1991 |